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Background
Shunt infection rates vary considerably depending on
patient's age, comorbidities, available follow up facilities
and definition of shunt infection, but the rates are gener-
ally considered to be unacceptable. Prophylactic antibiot-
ics cannot be shown to make a significant impact, and an
antimicrobial shunt has been developed. Approximately
60,000 of the Bactiseal™ shunts (Codman & Shurtleff Inc)
have been used worldwide over about 5 yrs. Complica-
tions, including infection, are expected to be reported to
the Company for notification to FDA. When such a report
of infection is received, the clinical data and removed
shunt are sent to BRIG UK for investigation. The results of
analysis of these reports are presented.
Materials and methods
Infections occurring in Bactiseal shunts were reported on
a proforma containing clinical information and sent
along with removed shunt components and any support-
ing material to BRIG, QMC, UK. The shunt components
were examined externally and each component (ventricu-
lar catheter, valve chamber, peritoneal catheter) asepti-
cally sampled for microscopy and culture. Isolates were
tested for MIC to clindamycin and rifampicin (R+C). Clin-
ical data were scrutinized and further information sought
from the reporting institution where necessary.
Results
Twenty-four infections were reported (though it is
accepted that under-reporting occurred). One was
excluded due to lack of data and shunt material. On inves-
tigation, 9 were found not to be infected. Of the remain-
ing 14 infections, 2 were due to gram-negative bacilli. In
5 cases, pre-operative CSF infection was present, all due to
R+C resistant Staphylococcus epidermidis. One case was pre-
sumed ventriculitis but showed no growth before or after
shunt removal. Two cases had further invasive shunt sur-
gery after the 2-month Bactiseal™ protection period. Two
cases were due to R+C – resistant S epidermidis contracted
at Bactiseal™ shunt insertion and the remaining 2 cases
were caused by R+C- susceptible Staphylococcus aureus and
should have been prevented.
Conclusion
Of the 24 "infections" reported, nine were not infected,
only four being contracted during shunt insertion, and
these should have been prevented. Audit of shunt infec-
tion must include a clear definition as well as "forensic"
microbiological assessment to yield accurate data.
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